1.00
Hdl Handle:
http://hdl.handle.net/10033/592833
Title:
Host cell mTORC1 is required for HCV RNA replication.
Authors:
Stöhr, Stefanie; Costa, Rui; Sandmann, Lisa; Westhaus, Sandra; Pfaender, Stephanie; Anggakusuma; Dazert, Eva; Meuleman, Philip; Vondran, Florian W R; Manns, Michael P; Steinmann, Eike; von Hahn, Thomas; Ciesek, Sandra
Abstract:
Chronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.
Affiliation:
TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.
Citation:
Host cell mTORC1 is required for HCV RNA replication. 2015: Gut
Journal:
Gut
Issue Date:
14-Aug-2015
URI:
http://hdl.handle.net/10033/592833
DOI:
10.1136/gutjnl-2014-308971
PubMed ID:
26276683
Type:
Article
ISSN:
1468-3288
Appears in Collections:
publications of the research group virus transmission ([TC]VIRT)

Full metadata record

DC FieldValue Language
dc.contributor.authorStöhr, Stefanieen
dc.contributor.authorCosta, Ruien
dc.contributor.authorSandmann, Lisaen
dc.contributor.authorWesthaus, Sandraen
dc.contributor.authorPfaender, Stephanieen
dc.contributor.authorAnggakusumaen
dc.contributor.authorDazert, Evaen
dc.contributor.authorMeuleman, Philipen
dc.contributor.authorVondran, Florian W Ren
dc.contributor.authorManns, Michael Pen
dc.contributor.authorSteinmann, Eikeen
dc.contributor.authorvon Hahn, Thomasen
dc.contributor.authorCiesek, Sandraen
dc.date.accessioned2016-01-05T13:52:18Zen
dc.date.available2016-01-05T13:52:18Zen
dc.date.issued2015-08-14en
dc.identifier.citationHost cell mTORC1 is required for HCV RNA replication. 2015: Guten
dc.identifier.issn1468-3288en
dc.identifier.pmid26276683en
dc.identifier.doi10.1136/gutjnl-2014-308971en
dc.identifier.urihttp://hdl.handle.net/10033/592833en
dc.description.abstractChronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.en
dc.languageENGen
dc.titleHost cell mTORC1 is required for HCV RNA replication.en
dc.typeArticleen
dc.contributor.departmentTWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.en
dc.identifier.journalGuten

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.